The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
Idiopathic Pulmonary Fibrosis (IPF)
The ASPIRE trial is a 52 week randomized, double-blind, placebo-controlled, parallel-group, multicenter trial in which the efficacy, safety, and pharmacokinetics of orally administered buloxibutid, either on top of stable IPF therapy or as monotherapy, are assessed in participants with IPF. Trial website: www.aspire-ipf.com
A Trial to Evaluate Efficacy and Safety of Buloxibutid in People With Idiopathic Pulmonary Fibrosis.
-
UAB Hospital, Birmingham, Alabama, United States, 35294
Paradigm Clinical Research, La Mesa, California, United States, 92942
Keck Medicine of University of Southern California, Los Angeles, California, United States, 90033
Paradigm Clinical Research Centers, Inc., Redding, California, United States, 96001
UC Davis Health System, Sacramento, California, United States, 95816
UC San Diego Medical Center - Hillcrest, San Diego, California, United States, 92103
National Jewish Medical and Research Center, Denver, Colorado, United States, 80206
University of Florida Health (UF Health), Gainesville, Florida, United States, 32610
Clinical Research Specialists, Kissimmee, Florida, United States, 34746
Emory Saint Joseph's Hospital, Atlanta, Georgia, United States, 30342
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
For general information about clinical research, read Learn About Studies.
40 Years to
ALL
No
Vicore Pharma AB,
2027-03